Quarterly Activity Report — Period ending 31 March 2021
Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study
Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study
Imagion Biosystems announced on ASX that it has received a total of $164,754 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on April 26, 2021. Please click to review the
Imagion Biosystems announced on ASX that it has received a total of $81,256.85 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on April 13, 2021. Please click to review the
Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems announced on ASX that it has received a total of $54,694.49 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 16 March 2021. Please click to review the
Imagion Biosystems is pleased to announce it is a proud recipient of an Innovations Connections grant from the Australian Government’s Department of Industry, Science, Energy
Imagion Biosystems announced on ASX that it has received a total of $245,059.82 for the exercise of options. Please click to review the full announcement
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
We have temporarily suspended our nanoparticle operations. Please revisit us in the future. We apologize for the inconvenience. Any questions, please email: info@imagionbio.com Dismiss